Trodelvy (sacituzumab govitecan-hziy) vs Orserdu (elacestrant) In a pivotal trial, patients treated with Orserdu demonstrated a median progression-free survival that was notably longer than those who received standard endocrine therapy, indicating its potential as an effective treatment option for ER-positive, HER2-negative breast cancer
How effective is Trodelvy and whats the success rate? - Drugs. com Treatment with Trodelvy aims to increase the length of time a patient lives, and also how long they live without their cancer progressing For most of these cancers, few other treatments are available
Trodelvy Is Effective in Real-World Patients With Breast Cancer Subset Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy For patients with metastatic triple-negative breast cancer, clinical activity with Trodelvy (sacituzumab govitecan) stays consistent, researchers found
Trodelvy: What to Expect, Side Effects, and More However, because SN-38 is linked to sacituzumab in Trodelvy, the medicine is able to target cancer cells with Trop-2 on them This makes Trodelvy less toxic to healthy cells and more effective in treating cancer cells
Physicians Discuss Elacestrant Vs Alternatives in ER+, HER2- MBC It will be an important point going forward because we are utilizing combination treatments much more commonly than endocrine monotherapy But outside of the context of that trial or any other ongoing studies, I wouldn't recommend combination strategies with elacestrant when we don't know the toxicity profile and any interactions
FDA Approves Orserdu and Expands Approval of Trodelvy® On February 3, 2023, the FDA expanded approval for sacituzumab govitecan (Trodelvy®, Gilead Sciences) for the treatment of people with HR-positive, HER2-negative MBC who have received at least two lines of therapy This new approval is based on results from the phase III TROPiCS-02 clinical trial
Elacestrant Alternatives Compared - Drugs. com Verzenio (abemaciclib) is a targeted oral therapy taken twice daily for HR-positive, HER2-negative early and advanced metastatic breast cancer It reduces cancer cell growth and spread Common side more Be the first to share your experience with this drug